ABL1-BCR Fusion FISH Probe
The ABL1-BCR Fusion FISH Probe is used to confirm a fusion of the ABL1 and BCR genes. The fusion of the ABL1 and BCR genes has been associated with Acute Myeloid Leukemia, Acute Myeloid Leukemia, and Acute Myeloid Leukemia. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| ABL1-BCR-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-RERE | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-REOR | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-REGO | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-REGR | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-OROR | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GORE | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GROR | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| ABL1-BCR-20-AQAQ | 20 (40 μL) | 200 μL |
|
ABL1 Gene Summary
This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014]
Gene Name: ABL Proto-oncogene 1, Non-receptor Tyrosine Kinase
Chromosome: CHR9: 133589267 -133763062
Locus: 9q34.12
BCR Gene Summary
A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Gene Name: BCR, RhoGEF And GTPase Activating Protein
Chromosome: CHR22: 23522551 -23660224
Locus: 22q11.23
Gene Diseases
The ABL1 BCR Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Acute Myeloid Leukemia |
| Acute Myeloid Leukemia |
| Acute Myeloid Leukemia |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|